A PHASE 1, OPEN-LABEL, MULTI-CENTER, NON-RANDOMIZED STUDY OF [F-18]SMS-5368 POSITRON EMISSION TOMOGRPHY IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL RECURRENCE AND NEGATIVE CONVENTIONAL IMAGING

被引：0
|
作者：
Hatcher, Paul A.
Culp, Stephen H.
von Gall, Carl C.
Osborne, Dustin R.
Fu, Yitong
Smith, William B.
Moolupuri, Abhi
Whitaker, Dustin L.
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP18-10
引用
收藏
页码：E304 / E304
页数：1
相关论文
共 43 条
  • [31] A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
    Park, K. H.
    Sohn, J. H.
    Lee, S.
    Park, J. H.
    Kang, S. Y.
    Kim, H. Y.
    Park, I. H.
    Park, Y. H.
    Im, Y. H.
    Lee, H. J.
    Hong, D. S.
    Park, S.
    Shin, S. H.
    Kwon, H. C.
    Seo, J. H.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1300 - 1306
  • [32] A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma
    Han, Xiaohong
    Zhang, Mingzhi
    Wang, Huaqing
    Zhang, Qingyuan
    Li, Wei
    Hao, Miaowang
    Gao, Yuhuan
    Jin, Jie
    Ren, Hanyun
    Tang, Yun
    Hong, Xiaonan
    Ke, Xiaoyan
    Su, Hang
    Gui, Lin
    Luo, Jianmin
    Xie, Liangzhi
    Gai, Wenlin
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (06) : 601 - 611
  • [33] A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab(SCT400) to rituximab(Mab Thera?) in patients with CD20-positive B-cell non-Hodgkin lymphoma
    Xiaohong Han
    Mingzhi Zhang
    Huaqing Wang
    Qingyuan Zhang
    Wei Li
    Miaowang Hao
    Yuhuan Gao
    Jie Jin
    Hanyun Ren
    Yun Tang
    Xiaonan Hong
    Xiaoyan Ke
    Hang Su
    Lin Gui
    Jianmin Luo
    Liangzhi Xie
    Wenlin Gai
    Yuankai Shi
    Chinese Journal of Cancer Research, 2022, 34 (06) : 601 - 611
  • [34] Care 001: multi-center randomized open-label phase II trial of neoadjuvant trastuzumab emtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER2-neu over-expressed breast cancer patients (TEAL study)
    Creamer, S. L.
    Patel, T. A.
    Ensor, J. E.
    Rodriguez, A. A.
    Niravath, P. A.
    Darcourt, J. G.
    Kaklamani, V. G.
    Meisel, J. L.
    Li, X.
    Zhao, J.
    Kuhn, J. G.
    Rosato, R. R.
    Qian, W.
    Belcheva, A.
    Boone, T.
    Chang, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Combination Therapy for Patients with High-risk non-muscle invasive Bladder Cancer (HR-NMIBC) A randomized, open-label, multi-center, world-wide, Phase III Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as a Combination Therapy compared to BCG alone in Patients with High-risk non-muscle invasive Bladder Cancer (POTOMAC) - AB 69/18 of the AUO
    Rexer, H.
    Merseburger, A.
    Boegemann, M.
    AKTUELLE UROLOGIE, 2019, 50 (04) : 345 - 346
  • [36] Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)
    Liu, Si-Yang Maggie
    Yan, Hong-Hong
    Wei, Xue-Wu
    Lu, Chang
    Dong, Xiao-Rong
    Du, Yingying
    Cui, Jiu-Wei
    Chen, Yuan
    Ma, Rui
    Wang, Bu-Hai
    Zhou, Zhen
    Cang, Shun-Dong
    Yang, Jin-Ji
    Tu, Hai-Yan
    Zhang, Xu-Chao
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    CLINICAL LUNG CANCER, 2022, 23 (07) : E395 - E399
  • [37] Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study
    Gottfried, M.
    Rosenberg, S. Keren
    Dudnik, J.
    Wollner, M.
    Bar, J.
    Onn, A.
    Frenkel, O.
    Maimon, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S90 - S91
  • [38] PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007)
    Lopez-Miranda, E.
    Gavila, J.
    Pernas, S.
    Saura, C.
    Oliveira, M.
    Serra, V.
    Schmid, P.
    Lord, S.
    Paez, D.
    Perez, J.
    Llombart, A.
    Petrovic, K.
    Dimitrijevic, S.
    Cortes, J.
    CANCER RESEARCH, 2017, 77
  • [39] A National, Multi Center, Randomized, Open-label, Phase II Study of Erlotinib Versus Gemcitabine (GEM) Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N2 Non-small-cell Lung Cancer (NSCLC) Patients (pts) With Activating EGFR Mutations (C-TONG 1103)
    Zhong, W.
    Wu, Y.
    Wang, C.
    Mao, W.
    Xu, L.
    Cheng, Y.
    Yang, X.
    Chen, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S602 - S603
  • [40] A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus-associated head and neck squamous cell cancer.
    Aggarwal, Charu
    Halmos, Balazs
    Porosnicu, Mercedes
    Saba, Nabil F.
    Sukari, Ammar
    Grethlein, Sara Jo
    Mehra, Ranee
    Adkins, Douglas
    Fidler, Mary J.
    Kumar, Rakesh
    Yang, Jie
    Abdullah, Shaad Essa
    Haigentz, Missak
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345